Skip to main content

Table 1 Baseline clinical, pharmacological, and laboratory characteristics of study patientsa

From: N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial

 

NAC group(n = 45)

Placebo group(n = 45)

P value

Baseline clinical characteristics

   

   Age, years

63.25 ± 9.78

65.09 ± 9.40

0.45

   Sex (male/female)

20/25

34/11

0.005

   Body mass index, kg/m2

28.56 ± 4.81

27.85 ± 4.13

0.45

   Time since diagnosis of DM, years

10.11 ± 8.50

9.82 ± 7.57

0.86

   Systolic blood pressure, mmHg

156.05 ± 19.9

151.95 ± 18.4

0.34

   Diastolic blood pressure, mmHg

82.63 ± 7.60

81.22 ± 7.14

0.39

   Ejection fraction, %

49.45 ± 10.99

46.83 ± 14.15

0.37

Medications

   

   Aspirin, n(%)

37(82.2%)

36(80%)

1.00

   ACE-inhibitors/ARB, n(%)

32(71.1%)

30(66.7%)

0.82

   β-blockers, n(%)

29(64.4%)

35(77.8%)

0.24

   Nitrates, n(%)

30(66.7%)

30(66.7%)

1.00

   Diuretics, n(%)

23(51.1%)

19(42.2%)

0.52

   Statins, n(%)

28(62.2%)

17(37.8%)

0.034

   Digitals, n(%)

6(13.3%)

6(13.3%)

1.00

Baseline laboratory values

   

   Serum creatinine, mg/dL

1.736 ± 0.42

1.736 ± 0.17

1.00

   Serum urea nitrogen, mg/dL

60.56 ± 28.37

58.64 ± 28.94

0.75

   Creatinine clearance, mL/min

42.76 ± 11.97

43.97 ± 11.91

0.63

  1. a All plus-minus values are mean ± SD. DM, diabetes mellitus; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers.